Table 1.

Table displaying distribution of variables between MDS-RS, MDS-RS-SLD, and MDS-RS-MLD

Variable; median value (range or %)	MDS-RS (n = 76)	SLD (n = 57)	MLD (n = 19)	P-value
Age (years)	73 (44–88)	73 (47–88)	72 (44–81)	0.22
No. of males	50 (66)	36 (63)	14 (74)	0.4
Hb; gm/dl	9.3 (5.8–14.4)	9.3 (5.8–13.4)	10 (7.8–14.4)	0.17
WBC count x 10⁹ per liter	5.1 (1.2–17.6)	5.7 (2.2–17.6)	4.4 (1.2–9.4)	0.02 *
ANC x 10⁹ per liter	3.06 (0.3–12.5)	3.2 (0.6–12.5)	2.13 (0.3–6.3)	0.02 *
Platelet count x 10⁹ per liter	237 (7–819)	255 (7–819)	202 (27–438)	0.05 *
BM ringed sideroblasts	35 (10–80)	50 (10–80)	20 (15–70)	0.004 *
BM blasts	1(0–4)	1(0–4)	1(0–3)	0.6
Cytogenetics
Abnormal karyotype (R-IPSS intermediate, poor and very poor cytogenetic risk groups)	6 (8)	4 (8)	2 (11)	0.5
IPSS cytogenetic risk groups
Good	69 (91)	52 (91)	17 (11)	0.5
Intermediate	2 (3)	2 (4)	0(0)
Poor	5 (6)	3 (5)	2 (11)
R-IPSS cytogenetic risk groups
Very good	2 (3)	1 (2)	1 (5)	0.6
Good	67 (88)	51 (89)	16 (84)
Intermediate	2 (3)	2 (4)	0(0)
Poor	4 (5)	2 (4)	2 (11)
Very poor	1 (1)	1 (2)	0(0)
Genomic abnormalities
SF3B1	49 (77)	41 (82)	8 (57)	0.06
ASXL1	10 (16)	6 (12)	4 (29)	0.15
DNMT3A	8 (13)	8 (16)	0(0)	0.04 *
TET2	4 (6)	4 (8)	0(0)	0.2
TP53	3 (5)	3 (6)	0(0)	0.2
IDH1	2 (3)	2 (4)	0(0)	0.3
SRSF2	1 (2)	1 (2)	0(0)	–
Others (PTPN11, ZRSR2, CSF3R, U2AF1)	4 (6)	4 (8)	0(0)	–
Treatment
HMA treatment	5 (7)	2 (4)	3 (16)	0.2
Immunomodulatory treatment (Lenalidomide)	1 (1)	1 (2)	0(0)	0.83
Allogeneic HSCT	2 (3)	1 (2)	1 (5)	0.16
Outcomes
Leukemic transformation	2 (3)	1 (2)	1 (5)	0.34
Overall survival; median months (range)	46 (0–190)	47 (0–190)	44 (6–123)	0.2

* Signify statistically significant values